They treated ovarian adenocarcinoma cell lines, OC-117-VGH (estrogen receptor-deficient) and OVCAR3 (estrogen receptor-positive), with different estrogen concentrations and observed differential effects on cell-cycle regulatory proteins. Here, ESR1 is linked to ovarian adenocarcinoma.